Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.565
-0.105 (-2.25%)
Aug 12, 2026, 3:45 PM EDT - Market open
Arbutus Biopharma Revenue
Arbutus Biopharma had revenue of $1.01M in the quarter ending June 30, 2026, a decrease of -90.56%. This brings the company's revenue in the last twelve months to $181.72M, up 1,078.78% year-over-year. In the year 2025, Arbutus Biopharma had annual revenue of $14.08M with 128.21% growth.
Revenue (ttm)
$181.72M
Revenue Growth
+1,078.78%
P/S Ratio
4.96
Revenue / Employee
$9,564,211
Employees
19
Market Cap
901.76M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.08M | 7.91M | 128.21% |
| Dec 31, 2024 | 6.17M | -11.97M | -65.98% |
| Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
| Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
| Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
| Dec 31, 2020 | 6.91M | 903.00K | 15.02% |
| Dec 31, 2019 | 6.01M | 66.00K | 1.11% |
| Dec 31, 2018 | 5.95M | -4.76M | -44.44% |
| Dec 31, 2017 | 10.70M | 9.21M | 617.64% |
| Dec 31, 2016 | 1.49M | -21.79M | -93.59% |
| Dec 31, 2015 | 23.28M | 8.32M | 55.66% |
| Dec 31, 2014 | 14.95M | -512.00K | -3.31% |
| Dec 31, 2013 | 15.47M | 1.36M | 9.64% |
| Dec 31, 2012 | 14.11M | -2.19M | -13.44% |
| Dec 31, 2011 | 16.30M | -5.13M | -23.95% |
| Dec 31, 2010 | 21.43M | 7.66M | 55.67% |
| Dec 31, 2009 | 13.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Theravance Biopharma | 104.31M |
| Kura Oncology | 71.64M |
| Aclaris Therapeutics | 8.22M |
| DBV Technologies | 5.04M |
ABUS News
- 8 hours ago - Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 hours ago - Arbutus Biopharma Quarterly report: Q2 2026 - Filings
- 8 hours ago - Arbutus Biopharma Earnings release: Q2 2026 - Filings
- 27 days ago - Arbutus Biopharma expects to return $230M in capital to shareholders - TheFly
- 27 days ago - Arbutus initiates patent infringement actions against Pfizer, BioNTech - TheFly
- 27 days ago - Arbutus Biopharma receives $178M settlement agreement from Moderna - TheFly
- 27 days ago - Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - GlobeNewsWire
- 3 months ago - Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire